Argentina
Colombia
Malaysia
Mexico
Other LatAm Countries
Adverse Event Management after Dengue Vaccination
Adverse events management after dengue vaccination is critical for ensuring patient safety, maintaining public trust, and compliance with global health regulations.
Dengue vaccines, like other vaccines, may cause side effects. Identifying and managing these adverse events effectively helps monitor vaccine safety, ensure risk-benefit balance established in clinical trials, and mitigate potential harm, especially in individuals with prior exposure to dengue where vaccination-associated risks could differ. Proper reporting also supports continuous improvement of vaccination programs.
Dengue vaccine adverse events (AEs) vary by individual health status and prior dengue exposure. AEs are also likely to vary by vaccine due to each candidate’s unique profile. Reported AEs include but are not limited to:
- Mild to Moderate Reactions: Fever, headache, muscle pain, fatigue, upper respiratory tract infections and injection site reactions.
- Moderate to Severe Reactions: Allergic reactions, rash, or joint pain.
- Serious Adverse Events (SAEs): Rare but may include severe allergic reactions like anaphylaxis
Monitoring and addressing these events are vital for proper vaccine administration.
Additional guidelines are also provided below for informational purposes.
Agency related guidelines for AE management
Third-party content and external links are provided for convenience only. Please note, it is the responsibility of the healthcare provider to ensure materials are up-to-date and in accordance with local treatment guidelines.
Agency related guidelines for clinical management of anaphylaxis
Third-party content and external links are provided for convenience only. Please note, it is the responsibility of the healthcare provider to ensure materials are up-to-date and in accordance with local treatment guidelines.
VV-MEDMAT-124022
